

THE LANCET **Oncology**

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Ahmed HU, Hindley RG, Dickinson L, et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. *Lancet Oncol* 2012; published online April 17. DOI:10.1016/S1470-2045(12)70121-3.

Focal Therapy for Localised Unifocal and Multifocal Prostate cancer: a prospective development study

Supplementary Table. Baseline characteristics in 41 men undergoing focal high intensity focused ultrasound in men with unifocal and multifocal localised prostate cancer: sub-group demographics according to ablation type.

Baseline characteristics	Type of ablation		
	Unilateral, one area (Figure 1a)	Bilateral, two areas (Figure 1b)	Midline, one area (Figure 1c)
N	20/41 (49%)	15/41 (37%)	6/41 (15%)
Age (years) *	63 (58.0 – 68.0)	60 (57.0 – 66.0)	63 (62.8 – 66.8)
Serum PSA (ng/ml) *	6.6 (5.1 – 9.2)	6.6 (6.0 – 7.4)	6.1 (5.0 – 8.7)
Gleason (TPM biopsies)			
3+3	6/20 (30%)	5/15 (33%)	2/6 (33%)
3+4	10/20 (50%)	10/15 (67%)	4/6 (67%)
4+3	4 (20%)	0 (0%)	0 (0%)
Clinical Stage			
T1c	19/20 (95%)	12/15 (80%)	6/6 (100%)
T2a	1/20 (5%)	3/15 (20%)	0 (0%)
NCCN risk category			
Low	5/20 (25%)	5/15 (33%)	1/6 (17%)
Intermediate	11/20 (55%)	10/15 (67%)	5/6 (83%)
High	4/20 (20%)	0 (0%)	0 (0%)

* median (interquartile range)